Grant Life Sciences (GLIF.OB) Enters Into Memorandum Of Understanding -MOU- To License Point-Of-Care -POC- Diagnostic Platform From AccuDx Inc.
10/19/2005 5:12:33 PM
RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 25, 2005--
Under proposed terms, Grant Life Sciences will control exclusive rights to rapid tests for HIV-1, HIV-2 and Dengue Fever, as well as a proprietary colloidal gold reagent, a key ingredient commonly used by leading manufacturers of rapid tests as a detectable label
comments powered by